News
Biologic therapy was associated with more than seven times greater odds of reaching sustained remission compared with ...
Older adults and those with a worse thyroid eye disease clinical activity score at baseline were less likely to respond to ...
Vamorolone showed promising results to effectively treat inflammation whilst minimising negative side compared to current ...
FDA Grants Orphan Drug Designation to Sanofi’s Rare Disease Drug Rilzabrutinib for wAIHA & IgG4-RD
Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...
Among patients with systemic autoimmune rheumatic diseases, hospitalization due to COVID-19 was more than twice as likely in ...
Long-term glucocorticoid (GC) use among older adults with late-onset rheumatoid arthritis (LORA) remains prevalent, despite its known adverse effects, according to study results published in ACR Open ...
The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...
Pharmaceutical Technology on MSN9d
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditionsSanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...
By pausing DMARDs, you may be ‘starting the cascade of getting the patient into trouble by interrupting therapy that’s ...
The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback